Kathryn Freidl, MD
Ophthalmology · Jacksonville, FLNPI 1134334105
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.0% of the total across 247 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 31 manufacturers reported payments, led by Alcon at 25.0% of the total.
Across 247 payments — averaging $38.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$2K
- AbbVie$1K
- Sight Sciences, Inc.$982
- NEW World Medical,inc.$801
- Glaukos Corporation$788
- Bausch & Lomb Americas Inc.$381
- plus $3K from 25 others
Across 95 payments — averaging $2611.93 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Alcon Research LLC$172K
- Glaukos Corporation$75K
- Ivantis, Inc$800
What the payments were for
- Consulting fees$1502%
- Speaking & faculty fees$320%
- Food & beverage$9,19698%
- Education$70%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 78 | $2,349 |
| AbbVie(2 entities) | 35 | $1,411 |
| Sight Sciences, Inc. | 8 | $982 |
| NEW World Medical,inc. | 15 | $801 |
| Glaukos Corporation | 22 | $788 |
| Bausch & Lomb Americas Inc. | 16 | $381 |
| Rxsight Inc | 4 | $288 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 8 | $286 |
| Nova Eye, Inc. | 1 | $258 |
| Aerie Pharmaceuticals, Inc. | 10 | $224 |
| Oyster Point Pharma, Inc. | 3 | $200 |
| Mallinckrodt Hospital Products Inc. | 9 | $192 |
| Johnson & Johnson Surgical Vision, Inc. | 6 | $180 |
| Amgen(2 entities) | 3 | $165 |
| Ivantis, Inc | 1 | $150 |
| Sun Pharmaceutical Industries Inc. | 5 | $147 |
| Iridex Corporation | 1 | $80 |
| Rayner Intraocular Lenses Limited | 3 | $72 |
| Harrow Eye, LLC | 3 | $68 |
| Sandoz | 2 | $61 |
| Tarsus Pharmaceuticals, Inc. | 2 | $46 |
| Kala Pharmaceuticals, Inc. | 2 | $44 |
| Biotissue Holdings Inc. | 1 | $38 |
| Novartis | 2 | $35 |
| Coherus Oncology, Inc. | 1 | $27 |
| Eyevance Pharmaceuticals LLC | 1 | $25 |
| Ocular Therapeutix, Inc. | 1 | $21 |
| Shire North American Group Inc | 1 | $20 |
| Apellis Pharmaceuticals, Inc. | 1 | $19 |
| Regeneron Healthcare Solutions, Inc. | 1 | $16 |
| Carl Zeiss Meditec USA, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OMNI(R) SURGICAL SYSTEM (US)$884
- XEN GLAUCOMA TREATMENT SYSTEM$614
- Clareon$606
- Ahmed Glaucoma Valve$442
- Kahook Dual Blade$442
- iStent$303
- enVista MX60 IOL$229
- iDoseTR$159
- Hydrus$150
- Clearpath$146
- Streamline$146
- Via360$146
- iStent inject W$144
- NGENUITY$144
- Luxor$144
- TYRVAYA$143
- RXSIGHT CONTACT LENS$140
- RXSIGHT INJECTOR CARTRIDGE$140
- RXSIGHT INJECTOR HANDPIECE$140
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$140
How this compares
$9,386 in reported general payments places this provider in the 85th percentile of 1,405 ophthalmology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 142 | $81,360 |
| RestasisCyclosporine | 63 | $64,735 |
| RocklatanNetarsudil Mesylat/Latanoprost | 77 | $49,507 |
| CombiganBrimonidine Tartrate/Timolol | 68 | $36,390 |
| XiidraLifitegrast | 32 | $34,931 |
| VyzultaLatanoprostene Bunod | 70 | $30,220 |
| RhopressaNetarsudil Mesylate | 48 | $24,445 |
| ProlensaBromfenac Sodium | 58 | $21,845 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 111 | $18,452 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 50 | $17,342 |
| Alphagan PBrimonidine Tartrate | 34 | $17,008 |
| Prednisolone Acetate | 414 | $15,992 |
| CequaCyclosporine | 12 | $15,822 |
| Dorzolamide-TimololDorzolamide/Timolol/Pf | 91 | $13,578 |
| MieboPerfluorohexyloctane/Pf | 18 | $13,542 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Restasis, Combigan, Alphagan P | $1,411 | $199,493307 claims |
| Bausch & Lomb Americas Inc.Xiidra, Vyzulta, Miebo | $381 | $78,693120 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa | $224 | $73,952125 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa, Loteprednol Etabonate | $286 | $24,83184 claims |
| AlconSimbrinza | $2,349 | $17,34250 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $147 | $15,82212 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,405 ophthalmology providers in Florida.
Other ophthalmology in Jacksonville
- Syril DorairajJacksonville$432K
- Frank BowdenJacksonville$169K
- David KostickJacksonville$108K
- Cathleen McCabeBradenton$2M
- Daniel KiernanSarasota$1.7M
- David EichenbaumSt Petersburg$1.7M
- Mark MilnerPalm Beach Gardens$1.2M
- Neel DesaiLargo$1M
- Jorge FortunPalm Beach Gardens$798K
- Courtney BoveeTampa$796K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.